Friday, June 8, 2012

Blaze Bioscience Gets $5M For Tumor Paint

Seattle-based Blaze Bioscience, a developer of technology it calls "tumor paint" to help physicians visualize solid, cancer tumors, has raised $5.0M in a Series A financing round, the firm said today. Source of the funding was not announced. Blaze, which is a spinout of the Fred Hutchinson Cancer Research Center, has developed a compound which binds to, and illuminates cancer cells, helping surgeons see and remove cancerous tissue. The firm said the new funding will go towards further advancing its technology. The technology being used by Blaze was created by Dr. Jim Olson at the Fred Hutchinson Cancer Research Center, which is licensing the technology to Blaze. More information »